Market Closed -
Nasdaq
16:00:00 2024-04-26 EDT
|
5-day change
|
1st Jan Change
|
0.7
USD
|
-0.14%
|
|
-0.06%
|
-76.11%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
564.3
|
104.6
|
25.86
|
119.3
|
28.81
|
-
|
-
|
Enterprise Value (EV)
1 |
411.7
|
20.55
|
-48.31
|
119.3
|
-15.29
|
-60.69
|
-103.4
|
P/E ratio
|
-4.93
x
|
-2.46
x
|
-0.56
x
|
-2.36
x
|
-0.6
x
|
-0.7
x
|
-0.72
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
11.8
x
|
6.26
x
|
22.2
x
|
12.5
x
|
EV / Revenue
|
-
|
-
|
-
|
11.8
x
|
-3.32
x
|
-46.7
x
|
-45
x
|
EV / EBITDA
|
-14,011,550
x
|
-489,413
x
|
1,023,258
x
|
-
|
-
|
-
|
-
|
EV / FCF
|
-14,918,977
x
|
-571,431
x
|
1,158,691
x
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-0%
|
0%
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
0.94
x
|
-0.17
x
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
23,214
|
23,463
|
23,560
|
40,711
|
41,153
|
-
|
-
|
Reference price
2 |
24.31
|
4.460
|
1.097
|
2.930
|
0.7000
|
0.7000
|
0.7000
|
Announcement Date
|
21-03-22
|
22-03-14
|
23-03-16
|
24-03-13
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
10.09
|
4.604
|
1.3
|
2.3
|
EBITDA
|
-29.38
|
-42
|
-47.21
|
-
|
-
|
-
|
-
|
EBIT
1 |
-29.42
|
-42.07
|
-47.28
|
-51.99
|
-48.03
|
-61.02
|
-68.16
|
Operating Margin
|
-
|
-
|
-
|
-515.34%
|
-1,043.18%
|
-4,694.21%
|
-2,963.6%
|
Earnings before Tax (EBT)
1 |
-29.54
|
-42.29
|
-46.18
|
-47.92
|
-49.69
|
-60.7
|
-73.77
|
Net income
1 |
-29.54
|
-42.29
|
-46.18
|
-47.92
|
-49.78
|
-60.4
|
-70.98
|
Net margin
|
-
|
-
|
-
|
-474.96%
|
-1,081.14%
|
-4,646.06%
|
-3,086%
|
EPS
2 |
-4.930
|
-1.810
|
-1.960
|
-1.240
|
-1.175
|
-1.005
|
-0.9775
|
Free Cash Flow
|
-27.59
|
-35.97
|
-41.69
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
21-03-22
|
22-03-14
|
23-03-16
|
24-03-13
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
1.964
|
2.165
|
3.073
|
2.887
|
1.158
|
1.229
|
1.301
|
0.9166
|
EBITDA
|
-11.38
|
-9.115
|
-
|
-11.87
|
-11.54
|
-12.09
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-11.4
|
-9.135
|
-11.73
|
-11.88
|
-11.56
|
-12.11
|
-13.2
|
-13.97
|
-13.66
|
-11.16
|
-11.96
|
-11.25
|
-11.14
|
-13.69
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-672.05%
|
-645.36%
|
-444.45%
|
-386.7%
|
-1,032.94%
|
-914.92%
|
-856.29%
|
-1,493.34%
|
Earnings before Tax (EBT)
1 |
-11.45
|
-9.184
|
-11.76
|
-11.87
|
-11.4
|
-11.14
|
-12.79
|
-12.82
|
-12.35
|
-9.95
|
-11.57
|
-10.86
|
-10.82
|
-16.46
|
Net income
1 |
-11.45
|
-9.184
|
-11.76
|
-11.87
|
-11.4
|
-11.14
|
-12.79
|
-12.82
|
-12.35
|
-9.95
|
-12.45
|
-11.71
|
-11.57
|
-14.07
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-651.27%
|
-592.33%
|
-402.02%
|
-344.65%
|
-1,075.14%
|
-952.49%
|
-889.55%
|
-1,534.96%
|
EPS
2 |
-0.4900
|
-0.3900
|
-0.5000
|
-0.5100
|
-0.4800
|
-0.4700
|
-0.4000
|
-0.3200
|
-0.3000
|
-0.2300
|
-0.3050
|
-0.2850
|
-0.2717
|
-0.3250
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
21-11-15
|
22-03-14
|
22-05-11
|
22-08-10
|
22-11-10
|
23-03-16
|
23-05-15
|
23-08-14
|
23-11-13
|
24-03-13
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
153
|
84.1
|
74.2
|
-
|
44.1
|
89.5
|
132
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-27.6
|
-36
|
-41.7
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
4.740
|
-6.350
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-4.590
|
-1.540
|
-1.770
|
-
|
-
|
-
|
-
|
Capex
|
0.07
|
0.09
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
21-03-22
|
22-03-14
|
23-03-16
|
24-03-13
|
-
|
-
|
-
|
Average target price
2.75
USD Spread / Average Target +292.86% Consensus |
1st Jan change
|
Capi.
|
---|
| -76.11% | 28.81M | | +1.51% | 42.75B | | +49.22% | 41.61B | | +8.57% | 41.34B | | -12.36% | 26.59B | | +8.92% | 25.49B | | -25.13% | 18.12B | | +29.17% | 12.24B | | -3.12% | 11.76B | | +6.35% | 11B |
Other Biotechnology & Medical Research
|